Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ETH-155008 / Shengke Pharmaceuticals
NCT04840784: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML	Terminated	1a/1b	9	RoW	ETH-155008, study drug	Shengke Pharmaceuticals Pty Ltd	NHL, Leukemia	05/23	05/23
NCT05758610: A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients	Recruiting	1	60	RoW	ETH-155008, Study drug	Shengke Pharmaceuticals (Jiangsu) Limited, China	NHL, Adult, AML, Adult Recurrent	12/25	06/26